Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to facilitate patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in four simple steps:
The Quirem Medical team will be present at the WCIO Annual Meeting in Boston, Massachusetts from 7 – 10 of June, 2018. In case you
The Quirem Medical team will be present at the SNMMI Annual Meeting in Philadelphia from 23-26 June 2018. In case you are interested in meeting
On May 4th 2018, the first patient in Turkey was treated with QuiremSpheres® at the Florence Nightingale Hospital in Istanbul. Prof. Dr. Murat Cantaşdemir and
Terumo and Quirem Medical welcome an important milestone for QuiremSpheres® in the Netherlands and in Europe. QuiremSpheres® is now reimbursed for liver-dominant, non-resectable, colorectal liver
On 15 December 2017, the first patient was included in the HEPAR Primary study by Dr. Arthur J.A.T. Braat at UMC Utrecht, the Netherlands. The
The Quirem Medical team will be present at ECIO in Vienna from 22-25 April 2018. Meet us at the Terumo booth to find out more
We are happy to announce that QuiremSpheres® will be fully reimbursed in Belgium as of 1 October 2017. Jan Sigger, CEO of Quirem Medical B.V.,
The Quirem Medical team will be present at EANM in Vienna from 21-24 October 2017. Meet us at the Terumo booth to find out more
The European launch of QuiremSpheres® was officially announced at CIRSE 2017 in Copenhagen, Denmark. QuiremSpheres® are now available to clinicians in various markets across Europe.
The Quirem Medical team will be present at CIRSE in Copenhagen from 16-20 September 2017. Meet us at the Terumo booth to find out more
Telephone: +31 85 0404170
E-mail: info.quirem@terumo-europe.com